Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prevacid Decline Is Weak Spot In Otherwise Strong Quarter For Abbott

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott posts robust 14% sales growth for the quarter driven by strong Humira performance, but acknowledges that Prevacid sales will be down as much as 10% for full year. The company believes, however, that the upside from Humira outweighs any downside from the performance of the TAP joint venture.

You may also be interested in...



Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA

The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.

Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA

The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.

Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott

Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel